Regeneron and Biogen both committed to Veeva Vault CRM this week, within hours of each other. Read as two customer wins, that is a good week for one vendor. Read as a pattern, it is a warning about what happens when an entire category of buyers converges on a single system of record, and marketing and commercial leaders outside life sciences should be paying attention now, while they still have leverage to do something about it.
The case for consolidation is real
I will state the strongest version of the other side first, because it is a genuinely good argument. Ryan Steinberger, Regeneron’s executive vice president and chief digital and technology officer, said: “We are pleased to expand our strategic partnership with Veeva by moving to Vault CRM, which will give our commercial teams a more connected platform and help them get faster access to the information they need for efficient decision-making.” Matt Farrell, Veeva’s president of commercial strategy, called it a way to extend “our strategic partnership with Regeneron to include Veeva Vault CRM as they continue to deliver important new medicines to people in need.”
That is not spin dressed up as strategy. Pharma commercial operations run on field interactions that are heavily regulated, and Vault CRM’s Agentic Call Report is specifically built to capture insight from those interactions that Veeva says was “previously lost to dropdowns and compliance concerns.” A platform built for one regulatory environment, sold to every company operating in that environment, genuinely is more efficient than a dozen custom-built alternatives. Specialization is not a dirty word. It is why vertical software exists at all.
What the specialization argument leaves out
Here is the counter-argument, and it is the one that should worry a CMO or RevOps leader watching this from outside pharma: efficiency and category dominance are not the same thing, and the more compliance-critical a workflow is, the harder it becomes to leave the vendor who runs it, regardless of price. When Regeneron and Biogen both move their commercial CRM to the same system in the same week, that is not two independent purchasing decisions converging by coincidence. It is a signal that the switching cost of building or maintaining an alternative has already crossed the point where even a company the size of Regeneron would rather not try.
That is precisely the moment a vendor’s negotiating leverage stops depending on being the best option and starts depending on being the only credible one. Nothing in either announcement suggests Veeva is behaving badly today. But pricing power does not announce itself in the renewal that follows consolidation. It shows up quietly, in the contract three or four renewal cycles later, after the internal skill to run anything else has atrophied and the compliance workflows are wired into one vendor’s data model.
This is not a pharma-only problem
Marketing and RevOps leaders in every vertical are living some version of this trade right now, usually with less regulatory cover to justify it. A CDP chosen because it is “where the identity graph already lives.” A CRM chosen because “that is what the industry standard is.” Composability was supposed to be the answer, the idea that a marketing stack could swap any single component without rebuilding the whole system. Vault CRM’s own pitch, that connecting commercial teams to one platform beats stitching several together, is the same logic that makes composability attractive in the pitch deck and expensive to actually execute once compliance, workflow and headcount are all built around one system.
What it means for the marketing leader
The lesson from this week is not “avoid category leaders.” Regeneron and Biogen made a rational choice given their constraints, and most buyers evaluating a compliance-heavy CRM should still take that specialization seriously rather than build around it out of principle. The lesson is to price the exit before signing the entry: ask what a full data export looks like in year one versus year four, ask whether the compliance workflow itself is portable or vendor-specific, and treat “everyone in our vertical is moving to this platform” as a reason to negotiate multi-year price protection now, not evidence the decision needs no further scrutiny. The category leader you pick while switching costs are still low is the one whose pricing you will be negotiating from a position of weakness later. That negotiation is a lot cheaper before the second competitor in your vertical signs.
See also: CRM vendors now compete on AI governance, not just agents, and why your CRM data is becoming someone else’s product, both early signs of the same leverage shift now playing out in life sciences.
Source: Veeva Systems / PR Newswire
